Abogen Biosciences

Abogen Biosciences (艾博生物) is a Suzhou-based clinical-stage biopharmaceutical company founded in early 2019 that develops messenger RNA (mRNA) drugs, built around proprietary mRNA and nano-delivery technology platforms . Its pipeline spans infectious-disease vaccines and oncology immunotherapy, with its most advanced program being a COVID-19 mRNA vaccine (ARCoV) developed with the Academy of Military Medical Sciences and Walvax Biotechnology, which became China's first mRNA vaccine to enter clinical trials in June 2020 and later received emergency use authorization in Indonesia . The company has since shifted significant resources toward oncology, with its KRAS-targeting mRNA therapeutic tumor vaccine securing FDA IND approval in May 2025—described by its investor 5Y Capital as placing Abogen "among the global leading ranks" in tumor immunotherapy . Earlier milestones include the 2023 NMPA approval of its first tumor mRNA drug candidate ABO2011 .

Abogen raised over $700 million in a Series C round in August 2021 with participation from Gaorong Ventures, followed by a $300 million Series C+ in November 2021 co-led by SoftBank Vision Fund and 5Y Capital . The company is led by founder and CEO Dr. Ying Bo (英博博士) .